Patents by Inventor Stéphane Loyau

Stéphane Loyau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACUTE ISCHEMIC STROKE
    Publication number: 20200138919
    Abstract: An easily administrable drug treatment to increase the recanalization rate associated with intravenously t-PA would represent a major advance in the acute ischemic stroke (AIS) management. The inventors demonstrate the presence of NETs network in intracranial thrombus extracted during AIS reperfusion procedures. Thrombi are encapsulated by these NETs network, which confer t-PA resistance. In fact, in presence of DNAse 1, t-PA-induced thrombolysisis accelerated, whereas DNAse alone is inefficient. These results suggest that a co-therapy associating t-PA and DNAse 1 may potentialize t-PA efficacy. Accordingly, the present invention relates to a method of treating an acute ischemic stroke (AIS) in a patient in need thereof comprising administering to the patient a therapeutically effective combination of t-PA and DNAse, wherein administration of the combination results in enhanced therapeutic efficacy relative to the administration of t-PA alone.
    Type: Application
    Filed: May 15, 2018
    Publication date: May 7, 2020
    Inventors: Jean-Philippe DESILLES, Véronique OLLIVIER, Benoit HOTIN-NOE, Mikhael MAZIGHI, Stéphane LOYAU, Jean-Baptiste MICHEL, Michel PIOTIN, Célina DUCROUX, Lucas DI MEGLIO, Raphaël BLANC, William BOISSEAU
  • Aminofucoidan as a vector for fibrinolysis in thrombotic diseases
    Patent number: 9999679
    Abstract: The invention relates to a vector targeting thrombus, having t-PA binding property consisting of a thrombus targeting fucoidan moiety, which is covalently linked to one or more t-PA binding amino groups by the reducing end of the said fucoidan moiety.
    Type: Grant
    Filed: March 21, 2014
    Date of Patent: June 19, 2018
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, UNIVERSITE PARIS XIII PARIS NORD, UNIVERSITE PARIS DIDEROT—PARIS 7
    Inventors: Stephane Loyau, Martine Jandrot-Perrus, Didier Letourneur, Frederic Chaubet, Benoit Ho-Tin-Noe, Murielle Maire, Jean-Baptiste Michel
  • AMINOFUCOIDAN AS A VECTOR FOR FIBRINOLYSIS IN THROMBOTIC DISEASES
    Publication number: 20160279249
    Abstract: The invention relates to a vector targeting thrombus, having t-PA binding property consisting of a thrombus targeting fucoidan moiety, which is covalently linked to one or more t-PA binding amino groups by the reducing end of the said fucoidan moiety.
    Type: Application
    Filed: March 21, 2014
    Publication date: September 29, 2016
    Applicants: INSTITUT DE LA SANTE ET DE LA RECHERCHE MEDICALE, UNIVERSITE PARIS XIII PARIS NORD, UNIVERSITE PARIS DIDEROT - PARIS 7
    Inventors: Stephane LOYAU, Martine JANDROT-PERRUS, Didier LETOURNEUR, Frederic CHAUBET, Benoit HO-TIN-NOE, Murielle MAIRE, Jean-Baptiste MICHEL
  • Method and kits for determining platelet susceptibility to activation in a patient
    Patent number: 9029095
    Abstract: The invention relates to methods and kits for determining platelet susceptibility to activation in a patient. More particularly, the present invention relates to a method for determining platelet susceptibility to activation in a patient, comprising a step consisting of measuring the level of GPVI dimers at the platelet surface in a blood sample obtained from said patient.
    Type: Grant
    Filed: December 1, 2011
    Date of Patent: May 12, 2015
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite Paris Diderot
    Inventors: Martine Jandrot-Perrus, Laurent Feldman, Stéphane Loyau
  • METHOD AND KITS FOR DETERMINING PLATELET SUSCEPTIBILITY TO ACTIVATION IN A PATIENT
    Publication number: 20130310401
    Abstract: The invention relates to methods and kits for determining platelet susceptibility to activation in a patient. More particularly, the present invention relates to a method for determining platelet susceptibility to activation in a patient, comprising a step consisting of measuring the level of GPVI dimers at the platelet surface in a blood sample obtained from said patient.
    Type: Application
    Filed: December 1, 2011
    Publication date: November 21, 2013
    Applicants: UNIVERSITE PARIS DIDEROT, Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Martine Jandrot-Perrus, Laurent Feldman, Stéphane Loyau